EVERSANA™ to expand into MENA region with Vector Pharma partnership

The strategic partnership facilitates ready-to-deploy commercial services to pharma companies across Middle East & North Africa

EVERSANA™, a leading next-gen commercial service provider catering to the global life sciences industry, has announced a strategic collaboration with the Dubai-based Vector Pharma FZCO with the aim of expanding services across the Middle Eastern & North African markets.  

With this, the two parties will provide pharmaceutical companies across MENA with ready-to-deploy commercial services and boost commercialization for those seeking to expand product access into the target markets.

Speaking on the latest development, Jim Lang, CEO of EVERSANA, mentioned that the company’s goal to address patient needs goes beyond geographic limitations and by combining Vector Pharma’s regional expertise with its own commercialization solutions, the two will accelerate patient access.

Among the offerings, services such as market access, pharmacovigilance, consultancy, medical communication, distribution, and further service expansion would also be provided by the partnership.

Samer Semaan, Managing Director of Vector Pharma, stated that the company’s aim for bringing innovative therapies closer to the native patients in need fits perfectly with EVERSANA’s global mission - benefitting patients, public health, and partners as well.

Headquartered in Dubai, UAE, Vector Pharma FZCO is a leading distributor of top-tier service products catering to oncology, rare disease, and highly specialized therapeutics across the MENA region and the Turkish market.

Imperative to note that EVERSANA’s mutually fruitful partnership with Vector intended for global growth has been accompanied with several other efforts of the company – such as the commercialization deals and investments made by the company across the EU, and the UK. 

In June 2021, EVERSANA disclosed a robust growth of the provider’s medical communications & integrated compliance services across 18 countries in Europe available in 10 native languages.

The company has a clientele expanding beyond 500 organizations, comprising of established and well-known pharmaceutical companies, and innovative start-ups, helping advance the portfolio of life sciences solutions for a healthier world.

Source Credit: https://www.biospace.com/article/releases/eversana-and-vector-pharma-fzco-announce-strategic-partnership-to-expand-commercialisation-services-throughout-middle-east-and-north-africa/